A CVS Health Corp. study demonstrated that the drug’s sales have plateaued and declined over the past few months. The study also found discontinuation rates of the drug were 8.1 percent, nearly four times higher than those in trials, according to the report.
More articles on gastroenterology:
New GI technology: 10 gastroenterologists on the most exciting advancements
Are current endoscope cleaning protocols enough?
A promising treatment for pancreatic cancer?
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.